Аналитики считают биотехнологическую компанию Dare Bioscience более перспективной инвестицией, чем Scilex

Dare Bioscience (NASDAQ:DARE – Get Free Report) and Scilex (NASDAQ:SCLX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends. Risk and Volatility Dare Bioscience has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Scilex has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Institutional and Insider Ownership 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Analyst Recommendations Dare Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 1,208.90%. Given Dare Bioscience’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Dare Bioscience is more favorable than Scilex. Profitability This table compares Dare Bioscience and Scilex’s net margins, return on equity and return on assets. Earnings & Valuation This table compares Dare Bioscience and Scilex”s gross revenue, earnings per share and valuation. Dare Bioscience has higher earnings, but lower revenue than Scilex. Dare Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Summary Dare Bioscience beats Scilex on 8 of the 14 factors compared between the two stocks. About Dare Bioscience Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. About Scilex Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.